NORTHWEST BIOTHERAPEUTICS, INC.(A Development Stage Company)CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share data)Years Ended December 31,Period from
Inception (March 18,
1996) to20122011December 31, 2012Revenues:Research material sales$
580Contract research and development from related parties--1,128Research grants and other772-1,833Total revenues772103,541Operating cost and expenses:Cost of research material sales--382Research and development28,90813,452119,172General and administration15,67513,33590,999Depreciation and amortization14102,377Loss on facility sublease--895Asset impairment loss--2,445Total operating costs and expenses44,59726,797216,270Loss from operations(43,825)(26,787)(212,729)Other income (expense):Valuation of reclassified equity instruments4918,82116,071Conversion inducement expense(9,103)(7,944)(27,337) Accretion of redeemable securities(2,042)-(2,042)Derivative valuation gain/(loss)6017281,383Gain on sale of intellectual property and property and equipment--3,664Interest expense(13,442)(7,648)(55,006)Interest income and other--1,707Net loss(67,320)(32,830)(274,289)Issuance of common stock in connection with elimination of Series A and Series A-1 preferred stock preferences--(12,349)Modification of Series A preferred stock warrants--(2,306)Modification of Series A-1 preferred stock warrants--(16,393)Series A preferred stock dividends--(334)Series A-1 preferred stock dividends--(917)Warrants issued on Series A and Series A-1 preferred stock dividends--(4,664)Accretion of Series A preferred stock mandatory redemption obligation--(1,872)Series A preferred stock redemption fee--(1,700)Beneficial conversion feature of Series D preferred stock--(4,274)Net loss applicable to common stock
|SOURCE Northwest Biotherapeutics|
Copyright©2012 PR Newswire.
All rights reserved